I write, again, compelled by emerging scientific facts regarding a serious systemic error of negligence on the part of the main American gynecological societies, AAGL and ACOG, and their member practitioners—though the problem I highlight here also affects overseas gynecological counterparts, specifically the RCOG in the United Kingdom.
William Kaelin and Gregg Semenza have a message for young scientists: do science for its own sake—and enjoy it.
Each year, the American Society of Clinical Oncology conducts its National Cancer Opinion Survey to better understand Americans' views on a wide range of cancer-related issues and uncover areas that need to be addressed.
Project GENIE (Genomics Evidence Neoplasia Information Exchange), an initiative by the American Association for Cancer Research, is launching a five-year, $36 million research collaboration with nine biopharmaceutical companies to obtain clinical and genomic data from an estimated 50,000 de-identified patients.
The European Commission has approved Astellas' oral once-daily therapy Xospata (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory (resistant to treatment) acute myeloid leukemia with a FLT3 mutation. Gilteritinib has the potential to improve treatment outcomes for AML patients with two forms of the most common mutation—FLT3 internal tandem duplication and FLT3 tyrosine kinase domain mutation.
FDA granted Shreis Scalene Sciences Breakthrough Device Designation for the Cytotron, a CE-marked, whole-body therapeutic medical device. The Center for Devices and Radiological Health granted the designation. The company’s designation request stated that “The Cytotron is intended to be used to cause degeneration of uncontrolled growth of tissues. It is indicated for treating protein-linked, abnormally […]
Ziopharm Oncology Inc. and MD Anderson Cancer Center established a research and development agreement relating to Ziopharm’s Sleeping Beauty immunotherapy program to use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors in T cells. “This new agreement is a launch point to expand our TCR library and execute two new clinical […]
African Americans and Hispanic people with multiple myeloma start treatment with a novel therapy significantly later than white patients, according to a study published Oct. 17 in Blood Advances.
Many non-white minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study from Dana-Farber Cancer Institute and University of Texas Southwestern.
The National Comprehensive Cancer Network published guidelines that provide step-by-step information on best practices in evaluating patients for hematopoietic cell transplantation and managing complications afterwards.
